Trial reportNature2021
Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans.
Registry-linked trialAbstract readClinical Trial, Phase IClinical Trial, Phase IIMulticenter Study
In one paragraph
Trial report in Nature, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05102643 (A Phase 1, Randomized, Double-blinded, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of SARS-CoV-2 DNA Vaccine Delivered Intramuscularly Followed by Electroporation for COVID-19 in Healthy Adults), which is not on this map. Cited by 241 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
241citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1, Randomized, Double-blinded, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of SARS-CoV-2 DNA Vaccine Delivered Intramuscularly Followed by Electroporation for COVID-19 in Healthy Adults
Who cites it
241 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Role of previous infection with SARS-CoV-2 in protecting against omicron reinfections and severe complications of COVID-19 compared to pre-omicron variants: a systematic review.BMC infectious diseases · 2023Pooled it
- Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines.The Journal of infectious diseases · 2022Pooled it
- Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine.Journal of virology · 2023Trial
- GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial.Cell reports. Medicine · 2023Trial
- Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Trial
- Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial.Nature microbiology · 2022Trial
- Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial.The lancet. HIV · 2022Trial
- Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming.The New England journal of medicine · 2022Trial
- A n-heneicosane solid emulsion as a single-dose subunit vaccine elicits broad and durable immune responses in an aged and a Pox virus model.International journal of pharmaceutics: X · 2026Article
- Waning immunity and the future of booster vaccination strategies in global vaccine programs post COVID-19.Human vaccines & immunotherapeutics · 2026Review
- Monoclonal antibodies target conserved S1mBio · 2026Article
- The immunogenicity and safety of adenoviral-based vaccines.Current opinion in allergy and clinical immunology · 2026Review
- Human primary antibody response to vaccination follows a partially sequential class-switching program with a checkpoint at IGHG2.Cell reports. Medicine · 2026Article
- Booster mRNA Vaccination Prevents Breakthrough Severe COVID-19 Infections.Journal of medical virology · 2026Article
- Long-term cross-variant Fc-mediated immune responses against SARS-CoV-2 induced by a heterologous adenoviral/inactivated virus prime-boost vaccination strategy.NPJ vaccines · 2026Article
- Humoral Immune Correlates Analysis of Four Vaccines Against SARS-CoV-2 in Rhesus Macaques.Research square · 2026Article
- Rapid and potent induction of protective mucosal immunity against SARS-CoV-2 by an adenovirus-vectored nanoparticle vaccine.Journal of nanobiotechnology · 2026Article
- A new mRNA antigen vaccine induces potent B and T cell responses and in vivo protection against SARS-CoV-2.NPJ vaccines · 2026Article
- Non-cytolytic re-engineering of a viral vaccine vector enables durable effector-memory T cell immunity by reinforcing type I IFN induction.Molecular therapy. Nucleic acids · 2026Article
- A new mRNA antigen vaccine induces potent B and T cell responses andbioRxiv : the preprint server for biology · 2026Article
181 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
31 authors.
Galit Alter *Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7680-9215
Jingyou Yu *Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Jinyan Liu *Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Abishek Chandrashekar *Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7821-5552
Erica N Borducchi *Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Lisa H Tostanoski *Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.ORCID http://orcid.org/0000-0001-9255-5684
Katherine McMahan *Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Catherine Jacob-Dolan *Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6641-0342
David R MartinezUniversity of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Aiquan ChangCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Tochi AniokeCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Michelle LiftonCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.ORCID http://orcid.org/0000-0003-0279-2198
Joseph NkololaCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Kathryn E StephensonCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Caroline AtyeoRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Sally ShinRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-9306-2264
Paul FieldsAdaptive Biotechnologies, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-9608-6464
Ian KaplanAdaptive Biotechnologies, Seattle, WA, USA.
Harlan RobinsAdaptive Biotechnologies, Seattle, WA, USA.
Fatima AmanatIcahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-8029-8227
Florian KrammerIcahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0003-4121-776X
Ralph S BaricUniversity of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0001-6827-8701
Mathieu Le GarsJanssen Vaccines & Prevention, Leiden, The Netherlands.
Jerald SadoffJanssen Vaccines & Prevention, Leiden, The Netherlands.
Anne Marit de GrootJanssen Vaccines & Prevention, Leiden, The Netherlands.
Dirk HeerweghJanssen Research & Development, Beerse, Belgium.
Frank StruyfJanssen Research & Development, Beerse, Belgium.ORCID http://orcid.org/0000-0001-9988-0260
Macaya DouoguihJanssen Vaccines & Prevention, Leiden, The Netherlands.
Johan van HoofJanssen Vaccines & Prevention, Leiden, The Netherlands.
Hanneke SchuitemakerJanssen Vaccines & Prevention, Leiden, The Netherlands.ORCID http://orcid.org/0000-0001-8563-2266
Dan H BarouchCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA. dbarouch@bidmc.harvard.edu.ORCID http://orcid.org/0000-0001-5127-4659
Funding
Multidisciplinary HIV Training ProgramT32AI007387 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Daniel R. Kuritzkes · 1990 to 2026
$8.8MINFECTIOUS DISEASE PATHOGENESIS TRAININGT32AI007151 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JULIANO, JONATHAN J · 1985 to 2024
$5.5MImmunologic Signatures of SARS-CoV-2 Vaccination and DiseaseU01CA260476 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H. · 2020 to 2024
$3.7MDefining viral and immune mechanisms of Dengue virus serotype 2 immune evasionF32AI152296 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MARTINEZ, DAVID R. · 2020 to 2020
$41kHoward Hughes Medical InstituteNCI NIH HHS U01 CA260476NIAID NIH HHS F32 AI152296NIAID NIH HHS T32 AI007151NIAID NIH HHS T32 AI007387NIH HHS AI007151NIH HHS AI152296Wellcome Trust
Abstract
The Ad26.COV2.S vaccine
Indexed as
Ad26COVS1AdolescentAdultAntibodies, NeutralizingAntibodies, ViralCOVID-19COVID-19 VaccinesHumansImmunity, CellularImmunity, HumoralMiddle AgedSARS-CoV-2Spike Glycoprotein, CoronavirusYoung AdultAd26COVS1Antibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT05102643ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.